Join to View Full Profile
18000 Studebaker RdSte 800Cerritos, CA 90703
Phone+1 562-735-3226
Dr. Mazumder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1979 - 1983
Baylor College of MedicineResidency, Internal Medicine, 1977 - 1979
Johns Hopkins University School of MedicineClass of 1977
Certifications & Licensure
CA State Medical License 2016 - 2026
NY State Medical License 1998 - 2023
DC State Medical License 1991 - 2013
MD State Medical License 1979 - 1991
TX State Medical License 1984 - 1986
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants with Relapsed/Refractory Cancer Indications
Roles: Principal Investigator, Contact
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2020 Sep 03
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 8 citationsFilanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.Darren Pan, Jonathan L Kaufman, Myo Htut, Manish Agrawal, Amitabha Mazumder
Cancer Medicine. 2022-01-01 - 8 citationsPatient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.Alessandra Larocca, Xavier Leleu, Cyrille Touzeau, Joan Bladé, Agne Paner
British Journal of Haematology. 2021-10-21 - 87 citationsMelflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple MyelomaPaul G. Richardson, Albert Oriol, Alessandra Larocca, Joan Bladé, Michele Cavo
Journal of Clinical Oncology. 2021-03-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
